Plamed Asia is a healthcare fieldwork specialist focused on providing services to market research companies and consulting firms in the medical industry throughout Asia. The company is engaged in conducting interviews and providing access to healthcare professionals.

Plamed Asia

SDKI provides market research and consulting services across various industries including economic analysis, industrial safety, and artificial intelligence. The company utilizes insights from a team of 800 researchers with extensive experience to inform business strategies.

SDKI

Plamed Asia | 354 followers on LinkedIn. Your one-stop source for seamless, high-quality healthcare fieldwork services in Asia. | Plamed Asia is your one-stop source for seamless, high-quality healthcare fieldwork services in Asia.

Please visit our website to learn more about our services.

Associate Director at Plamed Asia

Yuriko Takahashi

The Plamed Asia team traded laptops for fishing rods at a scenic Tokyo spot for an unforgettable team-building experience. 😎 First-time anglers and seasoned pros gathered by the water's edge, we cheer the hard work and achievement 🎉 with drumrolls and the surreal taste of sashimi. 360° surrounded by cherry blossoms 🌸 , what a lovely way to celebrate a magnificent spring day with our teammates! #PlamedAsia #TeamBonding #Teamwork #Collaboration #Healthcare #MedicalMarketResearch

On the eve of Lunar New Year, bid farewell to the old and usher in the new! 😀 Plamed Asia joins you in looking forward to the wonderful Year of the Dragon! Warmest blessings from our team in Hong Kong and China "Gong Xi Fa Cai! 恭喜發財!"

Our capability in Japan keeps expanding! Multiple CAR-T cell therapies have been approved in Japan, and several more will come soon. We are excited to share the details of the CAR-T landscape mapping project with 300 online surveys and 20 WATI interviews (including 14 treaters of CAR-T individual facilities).Our research last year aimed to map the current CAR-T cell therapy landscape and identify future opportunities in clinical practice. Check out the online portion of the project and stay tuned for the outcome of the qualitative part of this interesting project. Plamed Asia conducts healthcare projects in Japan, China, Korea and many other Asian markets. Contact our team at inquiry@plamedasia.com to discuss your proposal.

This is the festive season to express our heartfelt gratitude! The Plamed Asia team thanks our clients & industry colleagues for the fruitful collaborations and synergy in pursuing mutual goals and values. We are immensely grateful to our HCP panels, who trusted and supported us in completing many meaningful studies in Asia despite their busy work schedules. May your holidays be filled with joy, peace and precious moments with loved ones. We look forward to 2024, continue to be an essential part of your journey and achieve even more new milestones together! #Happyholidays #Happynewyear #hcps #Healthcare #Research #MedicalMarketResearch

We are thrilled to share the fascinating findings from a comprehensive study conducted in China (n=1000 HCPs), shedding light on the awareness and sales rep's visits of 51 leading international and domestic pharmaceutical companies. The study aimed to explore the dynamics between pharmaceutical representatives and healthcare providers, providing valuable insights into the evolving landscape of the Chinese pharmaceutical industry. Reach out to discuss its further implications: inquiry@plamedasia.com

Metric
Company Name	Plamed Asia	SDKI
Symbol
MSH ID	COM:PLAMEDASIA	JP:SDKI
Market	PRIVATE	PRIVATE
Sector	Commercial & Professional Services	Commercial & Professional Services
Industry	Market Research	Market Research & Consulting
Country	JP	JP
Stage
Employee Count
Website	plamedasia.com	sdki.jp
LinkedIn	plamedasia
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		52.28K
Web Traffic Growth		0.86
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

PLAM

COM:PLAMEDASIA

Plamed Asia

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue